Published in Cancer Cell on July 10, 2012
Getting TRAIL back on track for cancer therapy. Cell Death Differ (2014) 1.86
Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology (2013) 1.29
Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family. Cell Death Differ (2013) 1.27
Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions. J Clin Invest (2015) 1.24
Inhibition of VEGF-C modulates distal lymphatic remodeling and secondary metastasis. PLoS One (2013) 0.93
Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity. Oncogene (2015) 0.88
Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display. Proc Natl Acad Sci U S A (2015) 0.88
Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction. MAbs (2014) 0.83
CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants. Cell Death Dis (2014) 0.81
Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3. BMC Cancer (2014) 0.81
Poly(ADP-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression. J Biol Chem (2014) 0.80
Influence of the implantation site on the sensitivity of patient pancreatic tumor xenografts to Apo2L/TRAIL therapy. Pancreas (2014) 0.80
Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma. Cell Death Dis (2014) 0.79
Functional TRAIL receptors in monocytes and tumor-associated macrophages: A possible targeting pathway in the tumor microenvironment. Oncotarget (2016) 0.78
Co-acting gene networks predict TRAIL responsiveness of tumour cells with high accuracy. BMC Genomics (2014) 0.75
Tumor endothelial cells promote metastasis and cancer stem cell-like phenotype through elevated Epiregulin in esophageal cancer. Am J Cancer Res (2016) 0.75
Apoptotic agents. Transl Lung Cancer Res (2013) 0.75
Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma. Hum Vaccin Immunother (2015) 0.75
Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. Nat Rev Cancer (2017) 0.75
Endothelial cell apoptosis in angiogenesis and vessel regression. Cell Mol Life Sci (2017) 0.75
Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 75.09
The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature (2010) 10.04
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature (2006) 6.56
Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell (2009) 5.55
Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. Proc Natl Acad Sci U S A (2004) 5.15
p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature (2002) 4.56
Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell (2005) 4.14
Rapid redistribution of synaptic PSD-95 in the neocortex in vivo. PLoS Biol (2006) 4.12
Systematic evaluation of variability in ChIP-chip experiments using predefined DNA targets. Genome Res (2008) 4.08
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med (2007) 3.99
p63 protects the female germ line during meiotic arrest. Nature (2006) 3.98
Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res (2009) 3.72
Death receptor signal transducers: nodes of coordination in immune signaling networks. Nat Immunol (2009) 3.63
Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med (2002) 3.54
Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity. J Virol (2005) 3.54
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med (2012) 3.44
REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol Cell (2002) 3.29
Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res (2006) 2.84
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev (2003) 2.84
Tumor necrosis factor: an apoptosis JuNKie? Cell (2004) 2.64
Tomosyn inhibits synaptic vesicle priming in Caenorhabditis elegans. PLoS Biol (2006) 2.55
An integrated functional genomics screening program reveals a role for BMP-9 in glucose homeostasis. Nat Biotechnol (2003) 2.53
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol (2010) 2.43
Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc Natl Acad Sci U S A (2008) 2.30
Diverse modes of axon elaboration in the developing neocortex. PLoS Biol (2005) 2.26
An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell (2011) 2.14
NEMO and RIP1 control cell fate in response to extensive DNA damage via TNF-α feedforward signaling. Cell (2011) 2.13
Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Sci Transl Med (2011) 2.10
Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell (2003) 2.07
Crystal structure of BMP-9 and functional interactions with pro-region and receptors. J Biol Chem (2005) 2.03
Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol (2004) 1.99
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest (2009) 1.89
Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem (2004) 1.88
Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem (2005) 1.87
Pharmacological brake-release of mRNA translation enhances cognitive memory. Elife (2013) 1.85
Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation. Curr Opin Cell Biol (2010) 1.75
A C-terminal inhibitory domain controls the activity of p63 by an intramolecular mechanism. Mol Cell Biol (2002) 1.73
TWEAK attenuates the transition from innate to adaptive immunity. Cell (2005) 1.59
Chromatin immunoprecipitation for determining the association of proteins with specific genomic sequences in vivo. Curr Protoc Mol Biol (2005) 1.58
A caspase cascade regulating developmental axon degeneration. J Neurosci (2012) 1.57
Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. J Clin Oncol (2011) 1.55
Preservation of immunoreactivity and fine structure of adult C. elegans tissues using high-pressure freezing. J Histochem Cytochem (2004) 1.52
Secreted sulfatases Sulf1 and Sulf2 have overlapping yet essential roles in mouse neonatal survival. PLoS One (2007) 1.44
Identification of genes involved in synaptogenesis using a fluorescent active zone marker in Caenorhabditis elegans. J Neurosci (2005) 1.40
Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis. J Biol Chem (2005) 1.38
An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ. J Neurosci (2012) 1.36
TRAF2 Sets a threshold for extrinsic apoptosis by tagging caspase-8 with a ubiquitin shutoff timer. Mol Cell (2012) 1.34
An albumin-butyrylcholinesterase for cocaine toxicity and addiction: catalytic and pharmacokinetic properties. Chem Biol Interact (2008) 1.34
A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res (2010) 1.34
Can allodynic migraine patients be identified interictally using a questionnaire? Neurology (2005) 1.31
The Zon laboratory guide to positional cloning in zebrafish. Methods Cell Biol (2004) 1.30
The Caenorhabditis elegans vab-10 spectraplakin isoforms protect the epidermis against internal and external forces. J Cell Biol (2003) 1.30
Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy. Clin Cancer Res (2010) 1.29
APRIL-deficient mice have normal immune system development. Mol Cell Biol (2004) 1.29
pHUSH: a single vector system for conditional gene expression. BMC Biotechnol (2007) 1.27
Influences of aortic motion and curvature on vessel expansion in murine experimental aneurysms. Arterioscler Thromb Vasc Biol (2010) 1.26
Differential requirements for clathrin in receptor-mediated endocytosis and maintenance of synaptic vesicle pools. Proc Natl Acad Sci U S A (2009) 1.24
Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions. J Clin Invest (2015) 1.24
Priority medicines for maternal and child health: a global survey of national essential medicines lists. PLoS One (2012) 1.19
Regulation of axon degeneration after injury and in development by the endogenous calpain inhibitor calpastatin. Neuron (2013) 1.18
Death-receptor activation halts clathrin-dependent endocytosis. Proc Natl Acad Sci U S A (2006) 1.18
DNA methylation profiling defines clinically relevant biological subsets of non-small cell lung cancer. Clin Cancer Res (2012) 1.16
Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS One (2012) 1.15
Development of a long-acting insulin analog using albumin fusion technology. Diabetes (2005) 1.14
An automated method to quantify microglia morphology and application to monitor activation state longitudinally in vivo. PLoS One (2012) 1.14
Advancing translational research. Science (2011) 1.11
Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood (2007) 1.11
Death receptors DR6 and TROY regulate brain vascular development. Dev Cell (2012) 1.10
Highly efficient somatic-mutation identification using Escherichia coli mismatch-repair detection. Nat Methods (2007) 1.10
TWEAK induces apoptosis through a death-signaling complex comprising receptor-interacting protein 1 (RIP1), Fas-associated death domain (FADD), and caspase-8. J Biol Chem (2011) 1.10
Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. Blood (2007) 1.09
Comparative assessment of substrates and activity based probes as tools for non-invasive optical imaging of cysteine protease activity. PLoS One (2009) 1.08
X chromosome-linked inhibitor of apoptosis regulates cell death induction by proapoptotic receptor agonists. J Biol Chem (2009) 1.08
Spatially coordinated kinase signaling regulates local axon degeneration. J Neurosci (2012) 1.07
Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Cancer Res (2004) 1.06
High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck. PLoS One (2013) 1.05
Mutator suppression and escape from replication error-induced extinction in yeast. PLoS Genet (2011) 1.05
FGFR3 stimulates stearoyl CoA desaturase 1 activity to promote bladder tumor growth. Cancer Res (2012) 1.05
Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Clin Cancer Res (2008) 1.04
Androgen hormone action in prostatic carcinogenesis: stromal androgen receptors mediate prostate cancer progression, malignant transformation and metastasis. Carcinogenesis (2012) 1.03
Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. Clin Cancer Res (2013) 1.02
Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer. Mol Cancer Ther (2013) 1.02